Bicyclic pyrimidine nucleoside analogues (BCNAs) as highly selective and potent inhibitors of varicella-zoster virus replication

Journal of Antimicrobial Chemotherapy

Volumn 50, Issue 1, 2002, Pages 5-9

  Balzarini, Jan ^a   McGuigan, Christopher ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; 5' DEOXYNUCLEOTIDASE; ACICLOVIR; ACYCLIC NUCLEOSIDE; ADEFOVIR; ANTIVIRUS AGENT; CF 1368; CF 1743; CF 2002; CIDOFOVIR; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOSCARNET; NUCLEOSIDE; NUCLEOTIDASE; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; SORIVUDINE; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VIRUS ENZYME; FUSED HETEROCYCLIC RINGS; OXIDOREDUCTASE; PYRIMIDINE NUCLEOSIDE;

ANTIVIRAL ACTIVITY; BLOOD BRAIN BARRIER; CATABOLISM; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; ERYTHROCYTE; ESCHERICHIA COLI; GENETIC CODE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HERPES ZOSTER; HUMAN; LIPOPHILICITY; MOUSE; NONHUMAN; REVIEW; SIDE EFFECT; SIMIAN VIRUS; VARICELLA ZOSTER VIRUS; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; BIOAVAILABILITY; DRUG EFFECT; ENZYME SPECIFICITY; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CELLS, CULTURED; DIHYDROURACIL DEHYDROGENASE (NADP); HERPESVIRUS 1, HUMAN; HERPESVIRUS 3, HUMAN; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; NUCLEOSIDES; OXIDOREDUCTASES; PYRIMIDINE NUCLEOSIDES; SUBSTRATE SPECIFICITY; THYMIDINE KINASE; THYMIDINE PHOSPHORYLASE; VIRUS REPLICATION;

EID: 0035996085     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkf037     Document Type: Review

References (18)

1. Potent and selective inhibition of varicella-zoster virus (VZV) by nucleoside analogues with an unusual bicyclic base
2. Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain
3. E-5-(2-Bromovinyl)-2′-deoxyuridine: A potent and selective antiherpes agent
4. The antiviral spectrum of (E)-5-(2-bromovinyl) -2′-deoxyuridine
5. Susceptibilities of several drug-resistant varicella-zoster virus (VZV) strains to bicyclic pyrimidine nucleoside analogues (BCNAs)
6. Chemotherapy of varicella-zoster virus (VZV) by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides
7. Specific recognition of the bicyclic pyrimidine nucleoside analogues, a new class of highly potent and selective inhibitors of varicella-zoster virus (VZV), by the VZV-encoded thymidine kinase
8. Phosphorolysis of (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) and other 5-substituted 2′-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets
9. (E)-5-(2-Bromovinyl)-2′-deoxyuridine. A good substrate for mammalian pyrimidine nucleoside phosphorylases
10. Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase
11. Three-dimensional structure of thymidine phosphorylase from Escherichia coli at 2.8 Å resolution
12. Further additions to MolScript version 1.4, including reading and contouring of the electron-density maps
13. Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice
14. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice
15. Combined effects of bromovinyldeoxyuridine and fractionated or continuous administration of 5-fluorouracil in P388 leukemia-bearing mice
16. Sorivudine and 5-fluorouracil: A clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase
17. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-5-(2bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil
18. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs